Bioventus (NYSE:BVS) Reaches New 1-Year High - Still a Buy?

Shares of Bioventus Inc. (NYSE:BVS - Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $13.15 and last traded at $13.09, with a volume of 20910 shares trading hands. The stock had previously closed at $12.97.

Wall Street Analysts Forecast Growth

BVS has been the subject of several analyst reports. Canaccord Genuity Group upped their price target on Bioventus from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, August 13th. Craig Hallum raised their target price on shares of Bioventus from $12.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, September 27th.

Bioventus Price Performance

The company has a quick ratio of 0.96, a current ratio of 1.33 and a debt-to-equity ratio of 1.82. The stock has a fifty day moving average of $10.84 and a two-hundred day moving average of $7.72. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -37.97 and a beta of 0.90.

Bioventus (NYSE:BVS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The firm had revenue of $151.22 million during the quarter, compared to analysts' expectations of $137.70 million. During the same quarter last year, the business earned $0.14 earnings per share. On average, equities research analysts anticipate that Bioventus Inc. will post 0.4 earnings per share for the current year.

Insider Buying and Selling

In other Bioventus news, Director John A. Bartholdson acquired 25,500 shares of the firm's stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the transaction, the director now directly owns 6,939,357 shares of the company's stock, valued at approximately $59,331,502.35. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director John A. Bartholdson purchased 80,000 shares of the stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the acquisition, the director now directly owns 6,913,857 shares in the company, valued at $59,113,477.35. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John A. Bartholdson bought 25,500 shares of the stock in a transaction on Monday, August 19th. The stock was purchased at an average cost of $8.55 per share, with a total value of $218,025.00. Following the completion of the purchase, the director now directly owns 6,939,357 shares in the company, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 32.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bioventus

A number of large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in Bioventus in the first quarter valued at approximately $28,000. Lazard Asset Management LLC acquired a new position in shares of Bioventus during the 1st quarter valued at $40,000. HB Wealth Management LLC purchased a new stake in Bioventus during the 2nd quarter worth $60,000. SG Americas Securities LLC purchased a new stake in Bioventus during the 1st quarter worth $66,000. Finally, Burns Matteson Capital Management LLC acquired a new stake in Bioventus in the 2nd quarter valued at $67,000. Hedge funds and other institutional investors own 62.94% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.